T6081

Milciclib (PHA-848125) (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Phase 2.

Influenza virus-IN-2 (compound 19) is a potent inhibitor of influenza A virus with anti-influenza activities, exhibiting a CC50 of 150.85 μM and an EC50 of 2.58 μM. Concentration-dependently, Influenza virus-IN-2 inhibits the PAN endonuclease with an EC50 of 489.39 nM [1].

CXCR4 antagonist 7 (Compound PARA-B) is a potent CXCR4 inhibitor (IC50 = 9.3 nM) [1] applicable in research on HIV infection, inflammatory diseases, cancer, and WHIM syndrome.

Cathepsin X-IN-1 (compound 25) is a potent Cathepsin X inhibitor (IC50 = 7.13 μM) that reduces PC-3 cell migration with low cytotoxicity [1].

Alizapride is an antagonist of dopamine receptor. Alizapride can be used in human digestive disorders which is a potent antiemetic [1] [3].

Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].

Protizinic acid inhibits phospholipase A2 (PLA2) with an IC 50 of 210 μM. Protizinic acid has antiinflammatory and antipyretic activity which is an orally active non-steroidal antiinflammatory agent [1] [2].

GABAA receptor agent 6 (compound 2027) is a potent γ-GABAAR antagonist with low cellular membrane permeability (Ki = 0.56 μM) [1].

SARS-CoV-2-IN-15 (compound 11) is a niclosamide analogue exhibiting greater stability in human plasma and liver S9 enzyme assays compared to niclosamide. It enhances bioavailability and half-life upon oral administration and is a potent SARS-CoV-2 inhibitor with an IC50 of 0.49 μM [1].

Flupyrimin is the insect nicotinic acetylcholine receptor (nAChR) antagonist [1].